Menu
Recruiting NCT04085029

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

— Observational Oligometastasis Metastatic Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Oligometastasis, Metastatic Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Primary outcome measures

  • Occurrence of acute adverse events following radiotherapy [Time frame: 90 Days]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years of age
  • Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
  • Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
  • Patient must sign study-specific informed consent

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

United States · 5 centers
  • Duke Cancer Institute Cary — Cary
  • Durham Veterans Administration Health Care System (DVAHCS) — Durham
  • Duke University Medical Center — Durham
  • Duke Women's Cancer Care Raleigh — Raleigh
  • Duke Raleigh Hospital — Raleigh

Identifiers

NCT: NCT04085029 · Pro00103137

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗